Boston Scientific reported $172 million in profits during the company’s second quarter, continuing a positive financial trend following a $328-million profit reported in the company’s first quarter.
That $172 million in net income is a significant improvement from the second quarter of 2020, when the Marlborough company reported a loss of $153 million, an improvement of 212%.
“We delivered excellent results this quarter, with strong momentum throughout our portfolio and faster-than-market growth in most segments, fueled by our team’s dedication to customers and patients all over the world,” said Mike Mahoney, chairman and CEO, in a statement.
At the same time, Boston Scientific reported $3.077 billion in sales for the second quarter of 2021, compared to $2.003 during the same quarter a year prior, a 54% increase.
